Creative Planning Ocular Therapeutix, Inc Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Creative Planning holds 20,947 shares of OCUL stock, worth $178,049. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,947

Holding current value

$178,049

% of portfolio

0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	BUY	$6.45 - $9.23 $135,108 - $193,340	20,947 New	20,947 $182,000
Q1 2023 May 15, 2023	BUY	$2.79 - $6.27 $139 - $313	50 Added 0.36%	13,889 $73,000
Q4 2022 Feb 10, 2023	SELL	$2.61 - $4.41 $4,058 - $6,857	-1,555 Reduced 10.1%	13,839 $38,000
Q3 2022 Nov 03, 2022	BUY	$4.09 - $6.5 $62,961 - $100,061	15,394 New	15,394 $64,000
Q2 2021 Aug 04, 2021	SELL	$13.43 - $19.16 $350,294 - $499,750	-26,083 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$15.82 - $22.11 $39,281 - $54,899	2,483 Added 10.52%	26,083 $428,000
Q4 2020 Jan 29, 2021	BUY	$7.91 - $22.95 $39,550 - $114,750	5,000 Added 26.88%	23,600 $489,000
Q3 2020 Nov 05, 2020	BUY	$7.36 - $9.87 $136,896 - $183,582	18,600 New	18,600 $142,000
Q1 2020 May 05, 2020	SELL	$3.95 - $7.4 $73,916 - $138,476	-18,713 Closed	0 $0
Q4 2019 Jan 30, 2020	BUY	$2.57 - $4.73 $5,944 - $10,940	2,313 Added 14.1%	18,713 $74,000
Q3 2019 Nov 01, 2019	BUY	$3.04 - $5.32 $13,680 - $23,940	4,500 Added 37.82%	16,400 $50,000
Q2 2019 Jul 26, 2019	BUY	$2.46 - $4.52 $29,274 - $53,787	11,900 New	11,900 $52,000
Q4 2017 Jan 17, 2018	SELL	$3.73 - $6.37 $54,458 - $93,002	-14,600 Closed	0 $0
Q3 2017 Oct 17, 2017	BUY	$5.28 - $6.88 $77,088 - $100,448	14,600	14,600 $90,000

Others Institutions Holding OCUL

# of Institutions

171

Shares Held

138M

Call Options Held

150K

Put Options Held

225K

View Full List

About OCULAR THERAPEUTIX, INC

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $654M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

More about OCUL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account